Jiangnan University

Yongquan Chen

Hao Zhang

Gang Wang

Haiqin Chen

Jianxin Zhao

Zhennan Gu

Shenglong Zhu

Fengwei Tian

Yuanda Song

Xin Tang

Zhen Wang

Wei Chen

Bo Yang

Ninghan Feng

Chunlei Tang

Guangfei Hao

Xiaoyun Huang

Kai Du

Xiaoying Wang

Shanshan Zhao

He Gao

Jun Cao

Hongyan Qu

Tiantian Mei

Guozhen Cui

Kai Shan

Chengfeng Ge

Lengyun Wei

Haiqun Chen

Guosheng Wu

The invention provides a fusion protein for treating metabolic diseases, and a preparation method and use thereof. The fusion protein has a general formula of R1-L-R2 or R2-L-R1, wherein R1 is FGF21 protein, an FGF21 protein analog, or a similar peptide with the biological function of FGF21 protein; R2 is GIP, mutant GIP or a similar peptide with the biological function of GIP; and L is a linker peptide. The fusion protein of the present invention is used as a therapeutic agent or a pharmaceutical composition in the treatment of diseases associated with hyperglycemia and hyperlipidemia, including diabetes, obesity, steatohepatitis or cardiovascular diseases,

Fusion protein including GIP and FGF21 and compositions thereof

Disclosed is linoleic acid isomerases and their application in production of conjugated linoleic acid, which belongs to the technical fields of protein engineering and microbial engineering. The linoleic acid isomerase derived fromis used to produce the conjugated linoleic acid. The recombinantcontaining the linoleic acid isomerase of the invention is added into a reaction system containing linoleic acid and react for 3 h to produce conjugated linoleic acids. The conversion rate of the conjugated linoleic acid of the invented method ranges from 12.1% to 42.1%, and the percentage of cis9, trans11-CLA in the conjugated linoleic acid can reach 84.3% to 89.1%. The invention provides a method for using microorganisms to produce conjugated linoleic acids with high safety and yield where cis9, trans11-CLA isomer is the major form in the conjugated linoleic acid products.

Linoleic acid isomerase and its application in production of conjugated linoleic acid

Disclosed is a diacylglycerol acyltransferase 1, a recombinantcontaining the diacylglycerol acyltransferase 1, and application thereof in production of triacylglycerol. The diacylglycerol acyltransferase 1 of the invention has a function of catalyzing synthesis of triacylglycerol. After the recombinantcontaining the diacylglycerol acyltransferase 1 of the invention is subjected to induction culture for 48 h, the content of total fatty acid and triacylglycerol in the recombinantcontaining the diacylglycerol acyltransferase 1 can be respectively increased by 1.94 folds and 12.09 folds as compared with those ofwithout the recombinant diacylglycerol acyltransferase 1. The instant invention provides a method for improving the ability of microorganisms to produce polyunsaturated fatty acids (PUFAs) by means of genetic engineering.

Diacylglycerol acyltransferase 1 and application thereof in production of triacylglycerol

The disclosure discloses an anti-metabolic disorder FGF analog and an application thereof, and belongs to the technical field of medicines. According to the disclosure, modification is performed based on an FGF19 mutant NGM282 to obtain a FGF19 analog, and the FGF19 analog is used in treating liver impairment, metabolic disorders, obesity, overweight, metabolic syndrome, diabetes and dyslipidemia and has no side effects of elevated cholesterol and dietary decline in a therapeutic process.

FGF analog

The disclosure discloses a fatty acid synthase inhibitor and application thereof and belongs to the technical field of medical biology. The fatty acid synthase inhibitor of the disclosure can significantly inhibit the activity of fatty acid synthase without affecting normal expression, and adjust the ratio of fatty acids in cells. The fatty acid synthase inhibitor of the disclosure has a good tumor proliferation inhibitory effect, can arrest the growth cycle of tumor cells in the interphase, prevent tumor cell division, inhibit tumor cell proliferation, promote tumor cell apoptosis and exert a tumor treatment effect, can be used to treat tumors and metabolism related diseases, and has an important clinical application prospect.

Fatty acid synthase inhibitor and application thereof

The present disclosure discloses a preparation method and use of a double-target fusion protein, and belongs to the technical field of medicines. According to the present disclosure, a novel fusion protein is obtained by transforming an FGF19 sequence and fusing the FGF19 sequence with GLP-1. Compared with wild-type FGF19 and GLP-1, the novel fusion protein has a more long-acting and stable effect, further reduces the carcinogenic risk of FGF19, and can better relieve liver damage and correct metabolic disorder, obesity, overweight, metabolic syndrome, diabetes, dyslipidemia and other diseases. Besides, in treatment, there are no side effects of gastrointestinal discomforts such as diet decline caused by GLP-1 treatment. Therefore, the double-target fusion protein has a wide application prospect.

Fusion protein comprising fibroblast growth factor 19 (FGF 19) and glucagon-like peptide-1

The present disclosure discloses preparation ofCCFM698 thalli and application thereof in a feed additive, and belongs to the field of biological engineering and feed additives. The total fatty acid content of thedried thalli obtained by the present disclosure is 30%-40% by weight of the dried thalli, and the EPA content is 24% or more by weight of total fatty acids. The dosage of the dried thalli in the feed in the disclosure is 0.5-1.5% of the total weight of the basal feed. The thallus feed additive is reasonable in fatty acid composition and very high in EPA content and can be used for producing high-DHA eggs which are beneficial to body health of eaters. The DHA content in each of eggs laid by laying hens fed with the feed containing the feed additive of the present disclosure reaches about 120 mg which is obviously higher than that in the prior art.

Preparation ofCCFM698 thalli and application thereof in feed additive

It relates to &#x3c9;-3 fatty acid desaturase for the synthesis of pufas from, a plasmid containing the same, a recombinant microorganism containing the plasmid and its application. The invention also provides the use of the above &#x3c9;-3 fatty acid desaturase in the biosynthesis of PUFAs, especially to catalyze C20:4to C20:5at normal temperature, with catalytic efficiency 65%. The recombinant strain reached 31.5% of the total fatty acid, and the conversion rate to AA was up to 77.6%.

Parasitic phytophthora-derived omega-3 fatty acid desaturase for synthesizing polyunsaturated fatty acids, carrier containing fatty acid desaturase, recombinant microorganisms, and application thereof

It relates to aATCC32222 uracil auxotroph strain and a construction method thereof. In the present invention,ATCC32222 is used as a material and undergoes gene knockout through anmediated genetic manipulation technology, to obtain theuracil auxotroph. The method is of great significance for the basic theoretic researches of the oil producing fungusATCC32222 and product development.

[object Object]

The present invention provides novel fatty acid desaturases genes used for synthesis of polyunsaturated fatty acids, especially &#x3c9;3 desaturases (FADS15). The present invention also provides nucleic acid sequence coding the above-described desaturases, expression vector of the above-described desaturases and recombinant microorganism expressing above-described desaturases.

Fatty acid desaturase used in the biosynthesis of long chain omega-3 polyunsaturated fatty acids

The present invention provides novel fatty acid desaturases genes used for synthesis of polyunsaturated fatty acids, especially delta-9 desaturases (FADS9-I). The present invention also provides nucleic acid sequence coding the above-described desaturases, expression vector of the above-described desaturases and recombinant microorganism expressing above-described desaturases.

Delta-9 desaturase used in the biosynthesis of polyunsaturated fatty acids

The present invention provides novel fatty acid desaturases genes used for synthesis of polyunsaturated fatty acids, especially omega-3 desaturases (FADS15). The present invention also provides nucleic acid sequence coding the above-described desaturases, expression vector of the above-described desaturases and recombinant microorganism expressing above-described desaturases.

Growing community of inventors

Wuxi, China

Yongquan Chen